Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome

L. E. Chapman, B. A. Ellis, F. T. Koster, M. Sotir, T. G. Ksiazek, G. J. Mertz, P. E. Rollin, K. F. Baum, A. T. Pavia, J. C. Christenson, P. J. Rubin, H. M. Jolson, R. E. Behrman, A. S. Khan, L. J. Wilson Bell, G. L. Simpson, J. Hawk, R. C. Holman, C. J. Peters

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. HPS was subsequently laboratory confirmed in 30 persons and not confirmed in 105 persons with adequate specimens. Patients with HPS were significantly more likely than were hantavirus-negative patients to report myalgias from onset of symptoms through hospitalization, nausea at outpatient presentation, and diarrhea and nausea at the time of hospitalization; they were significantly less likely to report respiratory symptoms early in the illness. The groups did not differ with regard to time from the onset of illness to the point at which they sought care; time from onset, hospitalization, or enrollment to death was significantly shorter for patients with HPS. At the time of hospitalization, patients with HPS more commonly had myelocytes, metamyelocytes, or promyelocytes on a peripheral blood smear, and significantly more of them had thrombocytopenia, hemoconcentration, and hypocapnia. Patterns of clinical symptoms, the pace of clinical evolution, and specific clinical laboratory parameters discriminated between these 2 groups.

Original languageEnglish (US)
Pages (from-to)293-304
Number of pages12
JournalClinical Infectious Diseases
Volume34
Issue number3
DOIs
StatePublished - Feb 1 2002

Fingerprint

Hantavirus Pulmonary Syndrome
Hantavirus
Ribavirin
Granulocyte Precursor Cells
Hospitalization
Nausea
Hypocapnia
Myalgia
Thrombocytopenia
Disease Outbreaks
Diarrhea
Outpatients
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. / Chapman, L. E.; Ellis, B. A.; Koster, F. T.; Sotir, M.; Ksiazek, T. G.; Mertz, G. J.; Rollin, P. E.; Baum, K. F.; Pavia, A. T.; Christenson, J. C.; Rubin, P. J.; Jolson, H. M.; Behrman, R. E.; Khan, A. S.; Wilson Bell, L. J.; Simpson, G. L.; Hawk, J.; Holman, R. C.; Peters, C. J.

In: Clinical Infectious Diseases, Vol. 34, No. 3, 01.02.2002, p. 293-304.

Research output: Contribution to journalArticle

Chapman, LE, Ellis, BA, Koster, FT, Sotir, M, Ksiazek, TG, Mertz, GJ, Rollin, PE, Baum, KF, Pavia, AT, Christenson, JC, Rubin, PJ, Jolson, HM, Behrman, RE, Khan, AS, Wilson Bell, LJ, Simpson, GL, Hawk, J, Holman, RC & Peters, CJ 2002, 'Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome', Clinical Infectious Diseases, vol. 34, no. 3, pp. 293-304. https://doi.org/10.1086/324619
Chapman, L. E. ; Ellis, B. A. ; Koster, F. T. ; Sotir, M. ; Ksiazek, T. G. ; Mertz, G. J. ; Rollin, P. E. ; Baum, K. F. ; Pavia, A. T. ; Christenson, J. C. ; Rubin, P. J. ; Jolson, H. M. ; Behrman, R. E. ; Khan, A. S. ; Wilson Bell, L. J. ; Simpson, G. L. ; Hawk, J. ; Holman, R. C. ; Peters, C. J. / Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. In: Clinical Infectious Diseases. 2002 ; Vol. 34, No. 3. pp. 293-304.
@article{73dd3cb083764f0aa39970458077d338,
title = "Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome",
abstract = "To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. HPS was subsequently laboratory confirmed in 30 persons and not confirmed in 105 persons with adequate specimens. Patients with HPS were significantly more likely than were hantavirus-negative patients to report myalgias from onset of symptoms through hospitalization, nausea at outpatient presentation, and diarrhea and nausea at the time of hospitalization; they were significantly less likely to report respiratory symptoms early in the illness. The groups did not differ with regard to time from the onset of illness to the point at which they sought care; time from onset, hospitalization, or enrollment to death was significantly shorter for patients with HPS. At the time of hospitalization, patients with HPS more commonly had myelocytes, metamyelocytes, or promyelocytes on a peripheral blood smear, and significantly more of them had thrombocytopenia, hemoconcentration, and hypocapnia. Patterns of clinical symptoms, the pace of clinical evolution, and specific clinical laboratory parameters discriminated between these 2 groups.",
author = "Chapman, {L. E.} and Ellis, {B. A.} and Koster, {F. T.} and M. Sotir and Ksiazek, {T. G.} and Mertz, {G. J.} and Rollin, {P. E.} and Baum, {K. F.} and Pavia, {A. T.} and Christenson, {J. C.} and Rubin, {P. J.} and Jolson, {H. M.} and Behrman, {R. E.} and Khan, {A. S.} and {Wilson Bell}, {L. J.} and Simpson, {G. L.} and J. Hawk and Holman, {R. C.} and Peters, {C. J.}",
year = "2002",
month = "2",
day = "1",
doi = "10.1086/324619",
language = "English (US)",
volume = "34",
pages = "293--304",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome

AU - Chapman, L. E.

AU - Ellis, B. A.

AU - Koster, F. T.

AU - Sotir, M.

AU - Ksiazek, T. G.

AU - Mertz, G. J.

AU - Rollin, P. E.

AU - Baum, K. F.

AU - Pavia, A. T.

AU - Christenson, J. C.

AU - Rubin, P. J.

AU - Jolson, H. M.

AU - Behrman, R. E.

AU - Khan, A. S.

AU - Wilson Bell, L. J.

AU - Simpson, G. L.

AU - Hawk, J.

AU - Holman, R. C.

AU - Peters, C. J.

PY - 2002/2/1

Y1 - 2002/2/1

N2 - To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. HPS was subsequently laboratory confirmed in 30 persons and not confirmed in 105 persons with adequate specimens. Patients with HPS were significantly more likely than were hantavirus-negative patients to report myalgias from onset of symptoms through hospitalization, nausea at outpatient presentation, and diarrhea and nausea at the time of hospitalization; they were significantly less likely to report respiratory symptoms early in the illness. The groups did not differ with regard to time from the onset of illness to the point at which they sought care; time from onset, hospitalization, or enrollment to death was significantly shorter for patients with HPS. At the time of hospitalization, patients with HPS more commonly had myelocytes, metamyelocytes, or promyelocytes on a peripheral blood smear, and significantly more of them had thrombocytopenia, hemoconcentration, and hypocapnia. Patterns of clinical symptoms, the pace of clinical evolution, and specific clinical laboratory parameters discriminated between these 2 groups.

AB - To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. HPS was subsequently laboratory confirmed in 30 persons and not confirmed in 105 persons with adequate specimens. Patients with HPS were significantly more likely than were hantavirus-negative patients to report myalgias from onset of symptoms through hospitalization, nausea at outpatient presentation, and diarrhea and nausea at the time of hospitalization; they were significantly less likely to report respiratory symptoms early in the illness. The groups did not differ with regard to time from the onset of illness to the point at which they sought care; time from onset, hospitalization, or enrollment to death was significantly shorter for patients with HPS. At the time of hospitalization, patients with HPS more commonly had myelocytes, metamyelocytes, or promyelocytes on a peripheral blood smear, and significantly more of them had thrombocytopenia, hemoconcentration, and hypocapnia. Patterns of clinical symptoms, the pace of clinical evolution, and specific clinical laboratory parameters discriminated between these 2 groups.

UR - http://www.scopus.com/inward/record.url?scp=0036467252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036467252&partnerID=8YFLogxK

U2 - 10.1086/324619

DO - 10.1086/324619

M3 - Article

C2 - 11774075

AN - SCOPUS:0036467252

VL - 34

SP - 293

EP - 304

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -